Advanced Filters
noise

Rochester, Minnesota Clinical Trials

A listing of Rochester, Minnesota clinical trials actively recruiting patient volunteers.

Found 878 clinical trials

Longitudinal Autonomic Characterization as a Predictor for Secondary Medical Complications Post-SCI

The purpose of this research is to learn about how the body is able to balance changes in blood pressure, how that changes over time, and how these changes impact a participant's risk of developing medical problems.

18 - 75 years of age All Phase N/A
M Mariah Robran

Impact of RFA on Esophageal Distensibility and Mucosal Impedance

Patients undergoing ablative therapy for management of dysplastic Barrett's Esophagus (BE) will have decreased distensibility over the course of treatment, but improvement in mucosal impedance as BE epithelia is replaced by neosquamous epithelia. This information may lead to further research in predicting therapeutic response and complications. The purpose of this …

18 years of age All Phase N/A
C Clinical Trial Referral Office

Q702 for the Treatment of Patients With Hematologic Malignancies

This phase I trial tests the safety, side effects, and best dose of Q702 in treating patients with hematologic malignancies. Q702 is in a class of medications called immunomodulatory agents. It works by helping the immune system kill cancer cells and by helping the bone marrow to produce normal blood …

18 years of age All Phase 1
S Saad Omar

A Study of Genetic Influence on LDL Hyper-responsiveness in Patients Following a Ketogenic Diet

The purpose of this study is to identify whether individuals following a ketogenic diet who experience extreme LDL-C elevation, termed "hyper-responders", have identifiable genetic variations in genes involved in cholesterol absorption.

18 years of age All Phase N/A
C Clinical Trial Referral Office

Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease

This early phase I trial tests the safety, side effects and how well medication combinations of dasatinib, quercetin, fisetin and temozolomide work in treating patients with glioma for which the patient has received treatment in the past (previously treated) and for tumor cells that remain after attempts to treat the …

18 years of age All Phase 0
C Clinical Trial Referral Office

Molecular and ctDNA Characterization of High-Risk Endometrial Cancer

This study seeks to better understand the recurrence of high-risk endometrial cancer. It will collect information about cancer genetics to find out various hereditary or cancer specific genetic variants that may have a role in diagnosis or management and prognosis of cancer. It also seeks to develop a genetic results …

18 years of age Female Phase N/A
J Jun Deng, MD

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

The purpose of this phase 3 multicenter double-blind randomized study is to assess the use of taletrectinib in the early-stage non-small cell lung cancer (NSCLC). The study compares taletrectinib (study drug) versus placebo (sugar pill) in patients with ROS1-fusion positive stage IB, II, IIIA NSCLC. The study will evaluate if …

18 years of age All Phase 3
B Betty Monari

App-Based Optimization of Long-Term CPAP Adherence and Quality of Life

The purpose of this study is to optimize the time of CPAP usage to at least 6 hours a night for 6 nights per week for people who have OSA with the help of a smartphone application called SmartWell24. This application aims to target CPAP adherence.

18 years of age All Phase N/A
K Karin Lindstrom, PhD

Ketogenic Intervention for Bipolar Depression

The purpose of this study is to assess the clinical correlates of therapeutic precision ketosis in bipolar depression and to evaluate the cardiometabolic correlates associated with therapeutic precision ketosis in bipolar depression.

18 - 50 years of age All Phase N/A
C Cynthia MacKenzie, RN, BSN

Selumetinib for the Prevention of Plexiform Neurofibroma Growth in NF Type 1

Plexiform neurofibromas (PN) are known to cause significant morbidity in children with NF1. The recent FDA approval for selumetinib in children 2 years and older with inoperable symptomatic PN was based on the finding that selumetinib shrinks the majority of PN in children with NF1 and results in clinically meaningful …

1 - 8 years of age All Phase 2

Simplify language using AI